Jess Loren remembers loving the taste of Cap'n Crunch cereal. Coca-Cola. Snickers bars. But now, instead of a sweetness, "they taste bland," she says. Flavors are noticeably muted since she started a ...
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a ...
There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in record numbers, providers are warning of a troubling ripple effect: ...
GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress ...
The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.
The U.S. Food and Drug Administration just approved the pill form of weight-loss drug Wegovy for use in the U.S. The daily oral medication, made by Novo Nordisk, is the first of its kind used to treat ...
In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality compared with those not taking the drugs. The mortality benefit was statistically ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...
Weight-loss pills that harness the same mechanism as the wildly popular drugs Wegovy and Ozempic are coming to the U.S. On Monday Novo Nordisk announced that the U.S. Food and Drug Administration ...
DEC 15 (Reuters) - A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while ...
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects. By Paula Span Year after year, Mary Bucklew strategized with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback